title: Hobnail Variant of Papillary Thyroid Carcinoma: Clinicopathologic and Molecular Evidence of Progression to Undifferentiated Carcinoma in 2 Cases.
abstract: The hobnail variant (HV) of papillary thyroid carcinoma (PTC) is an unusual entity recently proposed as an aggressive variant of PTC. We describe the pathologic and molecular features of 2 cases of HV of PTC. Both tumors presented in stage III (pT3 pN1a M0). The first case was diagnosed in a 62-year-old man, whereas the second was in a 53-year-old woman. Both patients were treated with total thyroidectomy and radioactive iodine. The primary tumors showed a hobnail/micropapillary pattern in ≥50% of the neoplasm, and positivity for TTF-1, TTF-2, thyroglobulin (TG), cyclin D1, and p53. The Ki-67 index was 4.6% and 5%, respectively. In case 1, the tumor disclosed BRAFV600E and TERT C228T (124:G>A) promoter gene mutation, negativity for NRAS, HRAS, and KRAS mutations, and negativity for RET/PTC1, RET/PTC3, and PAX8/PPARγ rearrangements. After 11 years the patient died with cervical lymph node, bone, and liver metastases. In the liver metastasis, the tumor displayed columnar cell PTC areas (positive for TTF-1, TG, and BRAFV600E) merging with undifferentiated carcinoma (UC) areas (positive for TTF-1 and BRAFV600E; negative for TG). In case 2, the patient died 6 years after treatment with local recurrence and disseminated metastases to the lung, pleura, bone, and liver. The tumor recurrence showed a UC component (positive for cyclin D1 and p53; negative for TTF-1 and TG) with a residual HV of PTC (positive for cyclin D1, p53, TTF-1, and TG). No BRAF, TERT, NRAS, HRAS, nor KRAS mutations were detected in the primary tumor or recurrence in case 2. Our findings suggest that p53-positive HV is a very aggressive form of PTC prone to progression to UC.
authors.affiliation: *Department of Anatomic Pathology, Clinical University Hospital, Servicio Gallego de Salud (SERGAS), Health Research Institute of Santiago de Compostela (IDIS) †Department of Anatomic Pathology, Medical Faculty, University of Santiago de Compostela, Santiago de Compostela ‡Department of Anatomic Pathology, Hospital HM Puerta del Sur, Móstoles, Madrid, Spain §Institute of Research and Innovation in Health (i3S), University of Porto ∥Institute of Molecular Pathology and Immunology of the University of Porto ¶Medical Faculty, University of Porto #Department of Pathology, Hospital de S. João, Porto, Portugal.
authors.forename: José M
authors.initials: JM
authors.lastname: Cameselle-Teijeiro
authors.forename: Irene
authors.initials: I
authors.lastname: Rodríguez-Pérez
authors.forename: Ricardo
authors.initials: R
authors.lastname: Celestino
authors.forename: Catarina
authors.initials: C
authors.lastname: Eloy
authors.forename: Magalí
authors.initials: M
authors.lastname: Piso-Neira
authors.forename: Ihab
authors.initials: I
authors.lastname: Abdulkader-Nallib
authors.forename: Paula
authors.initials: P
authors.lastname: Soares
authors.forename: Manuel
authors.initials: M
authors.lastname: Sobrinho-Simões
mesh_terms: D014408:Biomarkers, Tumor / Q000378:metabolism; D002277:Carcinoma / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology*; D002291:Carcinoma, Papillary; D018450:Disease Progression; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D000077273:Thyroid Cancer, Papillary; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor